Published in J Neurosci on May 18, 2011
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Alzheimer's disease: synapses gone cold. Mol Neurodegener (2011) 1.43
Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum Mol Genet (2011) 1.38
Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2012) 1.38
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Prion protein at the crossroads of physiology and disease. Trends Neurosci (2011) 1.26
Prion propagation, toxicity and degradation. Nat Neurosci (2012) 1.25
Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. J Physiol (2012) 1.19
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol (2015) 1.11
Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther (2013) 1.07
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res Ther (2014) 1.03
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo. Mol Brain (2013) 1.01
Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun (2013) 1.00
NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis (2013) 0.99
Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener (2012) 0.98
β-Amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci (2013) 0.98
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion (2012) 0.97
The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc). J Neurosci (2012) 0.93
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma (2012) 0.90
Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain (2012) 0.90
Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J Biol Chem (2014) 0.88
Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. J Biol Chem (2015) 0.88
Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging (2012) 0.87
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem (2015) 0.86
The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers. FASEB J (2013) 0.86
Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Curr Alzheimer Res (2013) 0.85
Amyloid-β and proinflammatory cytokines utilize a prion protein-dependent pathway to activate NADPH oxidase and induce cofilin-actin rods in hippocampal neurons. PLoS One (2014) 0.85
Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity. J Neurosci (2014) 0.85
Sod1 deficiency reduces incubation time in mouse models of prion disease. PLoS One (2013) 0.84
High resolution imaging study of interactions between the 37 kDa/67 kDa laminin receptor and APP, beta-secretase and gamma-secretase in Alzheimer's disease. PLoS One (2014) 0.83
The P's and Q's of cellular PrP-Aβ interactions. Prion (2012) 0.83
Lipid rafts: linking prion protein to zinc transport and amyloid-β toxicity in Alzheimer's disease. Front Cell Dev Biol (2014) 0.83
Insoluble cellular prion protein and its association with prion and Alzheimer diseases. Prion (2011) 0.82
Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain (2015) 0.81
Cellular prion protein and Alzheimer disease: link to oligomeric amyloid-β and neuronal cell death. Prion (2012) 0.81
CSF prion protein concentration and cognition in patients with Alzheimer disease. Prion (2013) 0.81
Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo. Philos Trans R Soc Lond B Biol Sci (2013) 0.81
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther (2015) 0.81
Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain. PLoS One (2012) 0.81
Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn. Mol Neurodegener (2013) 0.80
The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species. Alzheimers Dement (2015) 0.80
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis (2012) 0.80
Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes. Mol Brain (2015) 0.80
Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci (2017) 0.79
Identification of a Compound That Disrupts Binding of Amyloid-β to the Prion Protein Using a Novel Fluorescence-based Assay. J Biol Chem (2015) 0.79
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. Neurosci Biobehav Rev (2016) 0.78
Iron is a specific cofactor for distinct oxidation- and aggregation-dependent Aβ toxicity mechanisms in a Drosophila model. Dis Model Mech (2015) 0.78
Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-β-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. J Biol Chem (2015) 0.78
The neurodegeneration in Alzheimer disease and the prion protein. Prion (2013) 0.78
Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. ACS Chem Neurosci (2013) 0.77
Regulation of Amyloid β Oligomer Binding to Neurons and Neurotoxicity by the Prion Protein-mGluR5 Complex. J Biol Chem (2016) 0.77
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking. Neural Plast (2016) 0.77
Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS One (2013) 0.77
Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease. Biochem Biophys Res Commun (2016) 0.76
Alzheimer's disease and prion protein. Intractable Rare Dis Res (2013) 0.76
Nanomedicine for prion disease treatment: new insights into the role of dendrimers. Prion (2013) 0.75
Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease. Iran J Basic Med Sci (2015) 0.75
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β. J Biol Chem (2012) 0.75
Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Neurobiol Dis (2016) 0.75
Functions of the cellular prion protein, the end of Moore's law, and Ockham's razor theory. Prion (2016) 0.75
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. Front Mol Neurosci (2017) 0.75
Plasma prion protein concentration and progression of Alzheimer disease. Prion (2014) 0.75
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Front Neurosci (2017) 0.75
Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. J Neurosci (2017) 0.75
Drosophila melanogaster Models of Metal-Related Human Diseases and Metal Toxicity. Int J Mol Sci (2017) 0.75
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab (2011) 3.68
Substrate-targeting gamma-secretase modulators. Nature (2008) 3.38
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
A checklist for ecological management of landscapes for conservation. Ecol Lett (2007) 2.76
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron (2003) 2.43
Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nat Neurosci (2003) 2.38
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
MRI findings and sleep apnea in children with Chiari I malformation. Pediatr Neurol (2013) 2.13
Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun (2011) 1.96
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med (2012) 1.92
Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. J Neurosci (2006) 1.92
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol (2004) 1.90
Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology (2002) 1.79
Breast lesions: evaluation with US strain imaging--clinical experience of multiple observers. Radiology (2006) 1.76
Spontaneous adrenal hemorrhage during pregnancy: a review of the literature and a case report of successful conservative management. Obstet Gynecol Surv (2005) 1.75
Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci (2009) 1.75
Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener (2009) 1.73
Methods for a randomized trial of weight-supported treadmill training versus conventional training for walking during inpatient rehabilitation after incomplete traumatic spinal cord injury. Neurorehabil Neural Repair (2003) 1.68
Inflammatory pseudotumor of the spleen associated with a clonal Epstein-Barr virus genome. Case report and review of the literature. Am J Clin Pathol (2003) 1.66
Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc (2008) 1.60
Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet (2003) 1.58
Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol (2010) 1.55
Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat Chem Biol (2011) 1.54
Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol (2008) 1.52
Chronic perineal pain caused by pudendal nerve entrapment: anatomy and CT-guided perineural injection technique. AJR Am J Roentgenol (2003) 1.51
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol (2006) 1.48
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci (2004) 1.46
Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. Radiology (2006) 1.46
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol (2006) 1.43
Validity of the walking scale for spinal cord injury and other domains of function in a multicenter clinical trial. Neurorehabil Neural Repair (2007) 1.41
Adult-onset nemaline myopathy presenting as respiratory failure. Respir Care (2008) 1.40
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Evaluation of a hospital-based community liaison pharmacy service in Northern Ireland. Pharm World Sci (2004) 1.36
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest (2014) 1.33
Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging (2010) 1.32
Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol (2005) 1.30
Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci (2003) 1.29
De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet (2013) 1.29
Endogenous acetylcholine lowers the threshold for long-term potentiation induction in the CA1 area through muscarinic receptor activation: in vivo study. Eur J Neurosci (2004) 1.28
Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci (2007) 1.26
Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis (2008) 1.23
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A (2009) 1.21
Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci (2004) 1.19
Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med (2009) 1.19
Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. Brain (2013) 1.19
Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology (2003) 1.18
Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mutat (2010) 1.17
Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients. J Endourol (2010) 1.15
Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci (2005) 1.15
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Effects of collagen fiber orientation on the response of biologically derived soft tissue biomaterials to cyclic loading. J Biomed Mater Res A (2007) 1.14
Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J Neurosci (2002) 1.13
Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. Genome Biol (2010) 1.12
Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia. Anesth Analg (2004) 1.12
Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J (2011) 1.10
Late-onset neuroaxonal leucoencephalopathy with spheroids and vascular amyloid. Eur Neurol (2003) 1.10
Pleural nodularity in a patient with pyrexia of unknown origin. Chest (2002) 1.07
Percutaneous renal cryoablation: experience treating 115 tumors. J Urol (2008) 1.07
Diagnosis of cavitating mesenteric lymph node syndrome in celiac disease using MRI. AJR Am J Roentgenol (2004) 1.05
Response of heterograft heart valve biomaterials to moderate cyclic loading. J Biomed Mater Res A (2004) 1.04
Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem (2010) 1.03
Removal of synaptic Ca²+-permeable AMPA receptors during sleep. J Neurosci (2011) 1.03
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol (2011) 1.03
CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. Brain (2013) 1.02
Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo. Mol Brain (2013) 1.01
Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain (2008) 1.00